AZN

AstraZeneca’s Imfinzi improves disease-free survival in high-risk NMIBC

AstraZeneca's Imfinzi shows promise in improving disease-free survival for high-risk non-muscle-invasive bladder cancer, as highlighted by recent POTOMAC trial results...

May 9, 2025

AstraZeneca Plc Calquence combo approved in EU for first-line MCL

AstraZeneca’s Calquence, combined with bendamustine and rituximab, is now EU approved for untreated mantle cell lymphoma, offering a significant survival advantage...

May 6, 2025

AstraZeneca Plc Breztri succeeds in Phase III asthma trials

AstraZeneca's Breztri has shown significant promise in treating uncontrolled asthma, meeting primary endpoints in the KALOS and LOGOS Phase III trials...

May 2, 2025

AstraZeneca Plc reports revenue up 10%, strong pipeline progress

AstraZeneca Plc's Q1 2025 results reveal strong growth and a focus on pipeline delivery, setting the stage for ambitious goals leading to 2030...

April 29, 2025

AstraZeneca Plc Enhertu trial hits key PFS goal

The DESTINY-Breast09 Phase III trial of Enhertu marks a breakthrough for HER2-positive metastatic breast cancer, showcasing superior efficacy over traditional therapies...

April 22, 2025

AstraZeneca Plc Enhertu approved in the EU for HER2 breast cancer

AstraZeneca and Daiichi Sankyo's Enhertu gains EU approval for treating HR-positive, HER2-low metastatic breast cancer, offering new hope for patients...

April 4, 2025

AstraZeneca’s Imfinzi granted FDA approval in the US for bladder cancer

AstraZeneca's Imfinzi has received FDA approval as a groundbreaking treatment for muscle-invasive bladder cancer, significantly improving patient outcomes in clinical trials...

March 31, 2025

AstraZeneca Plc advances cell therapy ambition, acquiring EsoBiotec

AstraZeneca is set to transform cancer treatment by acquiring EsoBiotec, a leader in in vivo cell therapies that promise quicker, more effective patient care...

March 17, 2025

AstraZeneca Plc Imfinzi demonstrates improved EFS in early stage gastric cancer

The MATTERHORN Phase III trial reveals promising results for AstraZeneca's Imfinzi in enhancing event-free survival for patients with early-stage gastric cancer...

March 7, 2025

AstraZeneca Plc Datroway approved in the US for metastatic breast cancer

AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases...

January 20, 2025

AstraZeneca’s Tagrisso approved in the EU for patients with unresectable NSCLC

AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials...

December 23, 2024

AstraZeneca plc 33.4% potential upside indicated by JP Morgan

AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 33.4% according to JP Morgan.AZN.LJP Morgan set a target price of 14,000 GBX for the company, which when compared..

December 11, 2024

AstraZeneca Plc Imfinzi approved in the US for limited-stage SCLC

AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...

December 5, 2024

AstraZeneca plc 33.5% potential upside indicated by JP Morgan

AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 33.5% according to JP Morgan.AZN.LJP Morgan set a target price of 14,000 GBX for the company, which when compared..

November 25, 2024

AstraZeneca plc 38.4% potential upside indicated by JP Morgan

AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 38.4% according to JP Morgan.AZN.LJP Morgan set a target price of 14,000 GBX for the company, which when compared..

November 15, 2024

AstraZeneca Plc expands US R&D and manufacturing footprint with $3.5b investment

AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint...

November 12, 2024

AstraZeneca Plc Tezspire meets primary endpoints in WAYPOINT trial

AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients...

November 8, 2024

AstraZeneca’s Wainzua recommended for approval in the UK

AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy...

October 21, 2024

AstraZeneca’s Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis

AstraZeneca plc (LON:AZN) Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated vasculitis that..

September 18, 2024

AstraZeneca plc -12.4% potential downside indicated by Deutsche

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -12.4% according to Deutsche.AZN.LDeutsche set a target price of 11,000 GBX for the company, which when compared to the..

September 6, 2024

News and Interview Alerts

Company Presentations

Poolbeg Pharma – Well Positioned for Success with CEO Jeremy Skillington

Time Finance Plc Q3 Results and Profit Upgrades with Ed Rimmer CEO (VIDEO)

Accrol Group Holdings Results Presentation 2024 (VIDEO)

Poolbeg Pharma A Strategic Vision, Pioneering the Future of Innovative Medicine

Q&As

ICG Enterprise Trust: Balancing growth, returns and risk (LON:ICGT)

1 April 2026

Hardman & Co

ICG Enterprise Trust FY’26 results: look to future realisations

11 June 2026

NB Private Equity Partners 2025 results: Looking to future realisations

29 May 2026

Chesnara Plc: Showing good operational progress

17 April 2026

Arbuthnot Banking Group Plc: 2025 lower margins, 2026 profit stability

1 April 2026

Green News

Thor Energy reports elevated hydrogen results at HY-Range project

9 June 2026

Drax agrees £548m cash acquisition of Bluefield Solar Income Fund

1 June 2026

Drax completes commissioning of Hirwaun Power Station

29 May 2026

Jubilee Metals seeks flexibility to fund Molefe region development

29 May 2026

View all Sustainable sectors, Plcs and news >>

Search

Latest Interviews

Scotch Corner Designer Village IPO Investor Presentation

BrokerTalk

Cerillion Backed by Strong Order Momentum and Clear Visibility, Cavendish

5 May 2026

ADX Energy latest research highlights “transformational period ahead”, Auctus Advisors

5 May 2026

Record sees continued inflows despite market headwinds, Edison Investment Research

29 April 2026

Likewise Group FY25 Results Highlight Ongoing Growth Momentum, Zeus

29 April 2026

Verici Dx Shows Strong Momentum with Impressive Q1 Growth, Singer Capital Markets

28 April 2026

Funds

Diverse Income Trust: UK equity outlook and reconstruction proposal (LON:DIVI)

11 June 2026

Biotech Growth Trust reports strong one-year performance

11 June 2026

Ruffer Investment Company delivers positive year-to-date gains

11 June 2026

Finsbury Growth & Income Trust highlights portfolio value in May

9 June 2026

GSK to acquire Biotech Growth Trust portfolio company Nuvalent for $10.6bn

9 June 2026

View all Funds, Market Insights and news >>

FTSE 100 News

British Land appoints Joanne McNamara as CEO

2 June 2026

Endeavour Mining reports fatal contractor incident at Lafigué mine

1 June 2026

AstraZeneca’s Imfinzi plus BCG approved by FDA for high-risk bladder cancer

29 May 2026

Scottish Mortgage Investment Trust reports strong annual returns

27 May 2026

UK Broker Ratings

Goodwin PLC (GDWN.L) Stock Analysis: A Hidden Gem in Specialty Industrial Machinery with Robust Revenue Growth

9 June 2026

FirstGroup PLC (FGP.L) Stock Analysis: Examining a Potential 50% Upside for Investors

9 June 2026

Chemring Group PLC (CHG.L) Stock Analysis: Aerospace & Defense Player with a 22% Upside Potential

9 June 2026

Hilton Food Group PLC (HFG.L) Stock Analysis: Uncovering a 34.97% Potential Upside in the Packaged Foods Sector

9 June 2026

ABERDEEN GROUP PLC (ABDN.L) Stock Analysis: Navigating the Investment Landscape with a 6.12% Dividend Yield

9 June 2026

AZN

AstraZeneca’s Imfinzi improves disease-free survival in high-risk NMIBC

AstraZeneca's Imfinzi shows promise in improving disease-free survival for high-risk non-muscle-invasive bladder cancer, as highlighted by recent POTOMAC trial results...

May 9, 2025

AstraZeneca Plc Calquence combo approved in EU for first-line MCL

AstraZeneca’s Calquence, combined with bendamustine and rituximab, is now EU approved for untreated mantle cell lymphoma, offering a significant survival advantage...

May 6, 2025

AstraZeneca Plc Breztri succeeds in Phase III asthma trials

AstraZeneca's Breztri has shown significant promise in treating uncontrolled asthma, meeting primary endpoints in the KALOS and LOGOS Phase III trials...

May 2, 2025

AstraZeneca Plc reports revenue up 10%, strong pipeline progress

AstraZeneca Plc's Q1 2025 results reveal strong growth and a focus on pipeline delivery, setting the stage for ambitious goals leading to 2030...

April 29, 2025

AstraZeneca Plc Enhertu trial hits key PFS goal

The DESTINY-Breast09 Phase III trial of Enhertu marks a breakthrough for HER2-positive metastatic breast cancer, showcasing superior efficacy over traditional therapies...

April 22, 2025

AstraZeneca Plc Enhertu approved in the EU for HER2 breast cancer

AstraZeneca and Daiichi Sankyo's Enhertu gains EU approval for treating HR-positive, HER2-low metastatic breast cancer, offering new hope for patients...

April 4, 2025

AstraZeneca’s Imfinzi granted FDA approval in the US for bladder cancer

AstraZeneca's Imfinzi has received FDA approval as a groundbreaking treatment for muscle-invasive bladder cancer, significantly improving patient outcomes in clinical trials...

March 31, 2025

AstraZeneca Plc advances cell therapy ambition, acquiring EsoBiotec

AstraZeneca is set to transform cancer treatment by acquiring EsoBiotec, a leader in in vivo cell therapies that promise quicker, more effective patient care...

March 17, 2025

AstraZeneca Plc Imfinzi demonstrates improved EFS in early stage gastric cancer

The MATTERHORN Phase III trial reveals promising results for AstraZeneca's Imfinzi in enhancing event-free survival for patients with early-stage gastric cancer...

March 7, 2025

AstraZeneca Plc Datroway approved in the US for metastatic breast cancer

AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases...

January 20, 2025

AstraZeneca’s Tagrisso approved in the EU for patients with unresectable NSCLC

AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials...

December 23, 2024

AstraZeneca plc 33.4% potential upside indicated by JP Morgan

December 11, 2024

AstraZeneca Plc Imfinzi approved in the US for limited-stage SCLC

AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...